MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study
暂无分享,去创建一个
A. D. Dei Tos | P. Casali | S. Ferrari | A. Gronchi | J. Martín-Broto | P. Picci | S. Stacchiotti | J. López-Guerrero | A. Poveda | S. Bagué | P. Collini | M. Gambarotti | S. Calabuig | A. López-pousa | A. Gutiérrez | E. Palassini | J. Cruz | R. Cubedo | J. Martínez-Trufero | R. Ramos | A. Fernández-Serra | P. Luna
[1] M. Barančík,et al. New insight into p-glycoprotein as a drug target. , 2012, Anti-cancer agents in medicinal chemistry.
[2] A. Llombart‐Bosch,et al. Tumor response assessment by modified Choi criteria in localized high‐risk soft tissue sarcoma treated with chemotherapy , 2012, Cancer.
[3] R. Boldrini,et al. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. , 2012, International journal of oncology.
[4] J. Martín-Broto,et al. Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas , 2012, PloS one.
[5] A. D. Dei Tos,et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Rousseau,et al. Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. , 2011, Anticancer research.
[7] C. Quezada,et al. FK506 confers chemosensitivity to anticancer drugs in glioblastoma multiforme cells by decreasing the expression of the multiple resistance-associated protein-1. , 2011, Biochemical and biophysical research communications.
[8] Jian Li,et al. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. , 2010, Lung cancer.
[9] Mansoor M. Amiji,et al. Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma , 2010, PloS one.
[10] Ping Chen,et al. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. , 2009, The International journal of biological markers.
[11] S. Cole,et al. Structural Determinants of Substrate Specificity Differences between Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP3 (ABCC3) , 2008, Drug Metabolism and Disposition.
[12] F. Ali-Osman,et al. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. , 2007, Current opinion in pharmacology.
[13] M. Haber,et al. Role of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer , 2007, IUBMB life.
[14] S. Ferrari,et al. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. , 2006, International journal of oncology.
[15] S. Cole,et al. Transport of glutathione and glutathione conjugates by MRP1. , 2006, Trends in pharmacological sciences.
[16] E. Touboul,et al. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients , 2006, British Journal of Cancer.
[17] Douglas,et al. MDR 1 Gene-specific Monoclonal Antibody C 494 Cross-Reacts with Pyruvate Carboxylase 1 , 2006 .
[18] A. Rydholm,et al. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. , 2005, Human pathology.
[19] Tsuyoshi Saito,et al. ATP‐binding cassette superfamily transporter gene expression in human soft tissue sarcomas , 2005, International journal of cancer.
[20] T. Ochi,et al. P-glycoprotein expression in soft-tissue sarcomas , 2005, Journal of Cancer Research and Clinical Oncology.
[21] S. Cole,et al. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. , 2004, Current drug metabolism.
[22] E. van den Berg,et al. Multidrug resistance proteins in primary and metastatic soft-tissue sarcomas: down-regulation of P-glycoprotein during metastatic progression. , 2004, Anticancer research.
[23] G. Altenberg. Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily. , 2004, Current medicinal chemistry. Anti-cancer agents.
[24] E. van den Berg,et al. Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. , 2003, European journal of cancer.
[25] N. Kinukawa,et al. Nuclear expression of Y‐box‐binding protein‐1 correlates with P‐glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma , 2003, The Journal of pathology.
[26] S. Ferrari,et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G. Demetri,et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[29] M. Kool,et al. A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.
[30] J. Blay,et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] C. Fisher,et al. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. , 2000, European journal of cancer.
[32] D. Hipfner,et al. Structural, mechanistic and clinical aspects of MRP1. , 1999, Biochimica et biophysica acta.
[33] M. Zalupski,et al. Multidrug resistance phenotype in high grade soft tissue sarcoma , 1999, Cancer.
[34] A. Santoro. Advanced soft tissue sarcoma: how many more trials with anthracyclines and ifosfamide? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] B. Dörken,et al. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Foekens,et al. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. , 1997, British Journal of Cancer.
[37] J. Nesland,et al. Synovial sarcoma: immunohistochemical expression of P-glycoprotein and glutathione S transferase-pi and clinical drug resistance. , 1997, Pathology, research and practice.
[38] D. Hipfner,et al. Location of a protease-hypersensitive region in the multidrug resistance protein (MRP) by mapping of the epitope of MRP-specific monoclonal antibody QCRL-1. , 1996, Cancer research.
[39] Costan,et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. , 1996, Cancer research.
[40] E. van der Velde,et al. Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] Y. Oshika,et al. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. , 1995, British Journal of Cancer.
[42] J. Hayes,et al. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. , 1995, Critical reviews in biochemistry and molecular biology.
[43] J. McKay,et al. Immunohistochemical localization of glutathione s‐transferases in sarcomas , 1994, The Journal of pathology.
[44] Thomas D. Schmittgen,et al. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .